The Global Health Body Sounds Alert Over Critical Shortage of Obesity Medications
Under 10% of people that would benefit from obesity jabs such as Wegovy have access to them, warns the global health agency as it releases its inaugural recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for broader and more equitable availability to this class of drugs.
Per estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"The latest guidelines affirms that obesity is a long-term condition that can be managed with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant barriers to broad availability to the jabs that can aid individuals in losing substantial weight, says the body.
Weight-Loss Drug Supply Crisis
Despite the present best projected outlook, the production of such drugs would only suffice for about 100 million people – less than 10% of eligible patients, per the health organization.
The advice urges governments and firms to widen access, by measures including licensing agreements.
Exclusive production rights on semaglutide – the main component of the drug Wegovy – is scheduled to end in several countries in 2026.
How Weight-Loss Drugs Operate
The injections imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users eat less.
Individuals typically start to lose weight within a few weeks of beginning the weekly injections.
Studies indicates users may put most of the weight back on within a year of stopping the drug, because their usual hunger return.
Being carrying excess weight increases your risk for experiencing diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity impacts people in all nations and was associated with over three and a half million fatalities worldwide in 2024, as per the health agency.
